A pilot study to assess the feasibility of a multicenter cluster randomized trial for the manage- ment of asymptomatic persons with a thrombophilia. J Genet Couns. 2009;18:475 482. 835. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045 2051. 836. Kamel H, Iadecola C. Brain-immune interactions and ischemic stroke: clinical implications. Arch Neurol. 2012;69:576 581. 837. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005;111:570 575. 838. Vittos O, Toana B, Vittos A, Moldoveanu E. Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker. Biomarkers. 2012;17:289 302. 839. Nambi V, Hoogeveen RC, Chambless L, Hu Y, Bang H, Coresh J, Ni H, Boerwinkle E, Mosley T, Sharrett R, Folsom AR, Ballantyne CM. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2009;40:376 381. 840. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and theAmerican HeartAssociation. Circulation. 2003;107:499 511. 841. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in appar- ently healthy men. N Engl J Med. 1997;336:973 979. 842. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. 